Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617954 · ClinicalTrials.gov registry record
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
A clinical trial, sponsored by Agendia.
- Completed
- Registry status
- 820
- Enrollment target
NCT01617954: Completed study, sponsored by Agendia.
NCT01617954 is a clinical trial that has completed, run by Agendia. The registered enrollment target is 820 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01617954 has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- 820 participants
- Enrollment target
Study Summary
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Primary Outcome
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result. A Chi-square test will be performed for the comparison of the two proportions.
Interventions
- DEVICE MammaPrint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-12 |
What the finished NCT01617954 record still lists
NCT01617954 is an observational study that tracks outcomes without assigning an intervention. The registered 820 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which MammaPrint is the first listed.
NCT01617954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01617954 about?
NCT01617954 is a clinical study titled "PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score". This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
What is the current status of trial NCT01617954?
This trial is currently completed. The enrollment target is 820 participants. The study started on 2012-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01617954?
The interventions under investigation include: MammaPrint (DEVICE).
Who is sponsoring clinical trial NCT01617954?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia